Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | FHIT | P49789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10577895 | 0.83 | MAPK1 (0.56) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20709995 | 0.83 | ALDH1A1 (0.49) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20551640 | 0.83 | MAPK1 (0.47) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20550730 | 0.83 | MAPK1 (0.49) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL18740146 | 0.82 | MAPK1 (0.46) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24133585 | 0.81 | ALDH1A1 (0.46) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23931394 | 0.81 | MAPT (0.46) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14053319 | 0.81 | MAPK1 (0.57) | GAAMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1496038 | 0.80 | GAA (0.52) | GAASMN1; SMN2MAPK1KMT2ANPC1 | |
| SCHEMBL31194492 | 0.80 | GAA (0.52) | GAAALDH1A1HPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| US-6444612-B1 | CONTROLLING PLANT DISEASES CAUSED BY FUNGUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| CN-1315943-A | Use of 5-amino-pyrazol-derivatives for combating micro-organisms | BAYER AG (DE) | 2001-10-03 | — | — | CN | disclosed |
| EP-1107956-A2 | USE OF 5-AMINO-PYRAZOL-DERIVATIVES FOR COMBATING MICRO-ORGANISMS | BAYER AG (DE) | 2001-06-20 | — | — | EP | disclosed |
| US-6100288-A | EFFICIENCY; PESTICIDES, AGRICULTURE, STORAGE, HYGIENE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-08-08 | — | — | US | disclosed |
| WO-2000011951-A2 | USE OF 5-AMINO-PYRAZOL-DERIVATIVES FOR COMBATING MICRO-ORGANISMS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-09 | — | — | WO | disclosed |
| US-5981566-A | FOR CONTROLLING ANIMAL PESTS, IN PARTICULAR INSECTS, ARACHNIDS AND NEMATODES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5843978-A | Acylated 5-aminopyrazoles and the use thereof to combat animal parasites | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| CN-1172479-A | Acylated 5-aminopyrrole | BAYER AG (DE) | 1998-02-04 | — | — | CN | disclosed |
| EP-0802907-A1 | ACYLATED 5-AMINOPYRAZOLES AND THE USE THEREOF TO COMBAT ANIMAL PARASITES | BAYER AG (DE) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021653-A1 | ACYLATED 5-AMINOPYRAZOLES AND THE USE THEREOF TO COMBAT ANIMAL PARASITES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | GAA 335/4885MAPT 2507/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.